The Regulators of Complement Activation (RCA) gene cluster comprises several tandemly arranged genes which share functions in the innate immune system. RCA members, such as complement receptor 2 (CR2), are well-established susceptibility genes in complex autoimmune diseases. Altered expression of RCA genes has been demonstrated at both the functional and genetic level, but the mechanism underlying their regulation are not fully characterised. We aimed to investigate the structural organisation of the RCA gene cluster to identify key regulatory elements that influence the expression of CR2 and other genes in this immunomodulatory region. Using 4C, we captured extensive CTCF-mediated chromatin looping across the RCA gene cluster in B cells and showed these were organised into two topological associated domains (TADs). Interestingly, the inter-TAD boundary was located within the CR1 gene at a well-characterised segmental duplication.
INTRODUCTION 1 2
The complement system is a major immune network of soluble proteins and membrane receptors 3 which elicit potent, innate responses against pathogens, immune complexes and apoptotic cells (1). 4
The complement system is activated by one of three major pathways (classical, alternative or lectin), 5 triggering a series of proteolytic cleavage events which ultimately converge to form the C3 6 convertase. The C3 convertase enzyme catalyses, in part, the formation of complement effector 7 peptides (C3a, C5a, C3b and C5b) which mediate local inflammation, cell lysis and cell clearance (1). 8
Additionally, complement components are capable of binding to numerous immune cell types and 9 activating other immune pathways, including adaptive B cell and T cell responses (2, 3) . Complement 10 therefore represents an important bridge between the innate and adaptive immune systems and 11 allows for effective co-ordination of immune responses (4) . 12 13 The complement cascade is intricately controlled to ensure a sufficient immune response is generated 14 while preventing damage to self (1). In humans, a number of these regulatory proteins are located in a 15 gene cluster known as the Regulators of Complement Activation (RCA) at chromosome 1q32.2 (5) . 16 This includes the plasma protein C4 binding protein (encoded by alpha (C4BPA) and beta (C4BPB) 17 subunits), and several membrane receptors: decay-accelerating factor (DAF, CD55), complement 18 receptors 2 and 1 (CR2 and CR1), and membrane co-factor protein (MCP, CD46) (5) . Several 19 duplicated pseudogenes within the RCA cluster have also been identified (6, 7) of which CR1-like 20 (CR1L) has been best characterised (8) . All members of the RCA gene cluster are composed of 21 tandem 60 -70 amino acid motifs known as short consensus repeats (SCRs) which bind complement 22 components and primarily regulate the complement response through inhibition or activation of C3 23 convertase (1). As such, this gene cluster is believed to have been derived from complex duplications 24 of a common ancestral gene, followed by the diversification of function (5) . In addition to their 25 important role in innate immune response, members of RCA gene cluster are also involved in the 26 process of tissue injury, inflammation and apoptosis. Accordingly, they have been implicated in a 27 range of inflammatory and autoimmune disorders (9) (10) (11) (12) . 28 
29
A role for CR2 has been well established in the autoimmune disease, Systemic Lupus Erythematosus 30 (SLE). SLE is characterised by the presence of antibodies directed against nuclear antigens and has 31 a complex aetiology with a strong genetic component (13, 14) . CR2 regulates B cell responses by 32 modulating B cell activation and antibody production upon binding of complement-tagged antigens 33 (15) . Aberrant expression of CR2 on the surface of B cells has been demonstrated in both mouse 34 models of the disease (16, 17) and SLE patients (18, 19) , which functionally contributes to B cell 35 autoreactivity and autoimmune disease susceptibility (20) (21) (22) . Additionally, the CR2 gene has also 36 been implicated in SLE at the genetic level through linkage analyses (23) (24) (25) and association studies 37 (25) (26) (27) . Most recently, a SNP within the first intron of CR2 (rs1876453) was shown to alter the 38 expression of the neighbouring gene (CR1) without influencing CR2 expression (27) , indicating that 39 expression of these genes in the RCA cluster may be co-regulated. Functionally, rs1876453 was 40 compartments known as topologically associated domains (TADs) (30) . The current model proposed 48
to explain TAD formation involves CTCF and the cohesin complex, whereby loops are dynamically 49 formed through 'loop extrusion' between distal CTCF sites in convergent or 'forward-facing ' 50 orientation (31) . TADs are recognised to be constitutively maintained in different cell types but may 51 alternate between active ("A") and inactive ("B") compartment types depending on the cellular context 52 (32, 33) . While genes within the same TAD tend to be co-expressed, not all genes within a TAD are 53 necessarily expressed simultaneously. Rather, in a given context, TADs restrict chromatin interactions 54 between genes and distal regulatory elements, such as enhancers, to ensure that gene expression is 55
properly controlled (32, 34) . 56
57
Enhancers represent an important class of distal-regulatory elements which are largely responsible 58 for governing cell-type specific gene expression patterns (35) . Enhancers bind transcription factors to 59 upregulate expression of genes and are located distal to gene promoters in the linear genome but are 60 positioned in close proximity by chromatin looping (35) . Importantly, the majority of disease-61 associated SNPs from genome-wide association studies (GWAS) fall within enhancer regions (36) . 62 Enhancer elements have been predicted in the genome by the presence of epigenetic marks such as 63 enrichment of H3K27ac and expression of short, bi-directional transcripts termed enhancer RNA 64 (eRNA) (37, 38) . However, enhancers can simultaneously regulate expression of multiple genes, 65 regulate genes large distances away and skip their neighbouring gene/s, which has hindered the 66 identification of their target gene/s (35) . The mapping of chromatin interactions through high-67
throughput chromatin conformation capture technologies, such as Hi-C and capture Hi-C (CHi-C), has 68 aided in this, but the physical chromatin interactions detected using these methods may not 69 necessarily be functional (39) . As such, experimental validation of enhancers and physically 70 associating enhancer-gene pairs is imperative for understanding their influence on gene expression 71 (35, (39) (40) (41) . 72
73
The aim of this investigation was to explore the structural organisation of the RCA gene cluster in 74 order to identity regulatory elements which may co-regulate the expression of genes in this important 75 immunomodulatory cluster. In this study, we examined genomic interactions across the RCA gene 76 cluster using chromosome conformation capture and showed that long-range chromatin interactions 77 are involved in the co-regulation and co-expression of several RCA members in the B cell lineage. 78
Further, we identified an intragenic TAD boundary which organises chromatin interactions in the RCA 79 gene cluster into two discrete domains. Importantly, we functionally interrogated a putative long-range 80 enhancer and demonstrated that it regulates two genes simultaneously within a TAD in B cells. 81
Collectively, we have revealed how three-dimensional chromatin organisation plays an important role 82 in regulating the RCA gene cluster and have uncovered novel regulatory loci which govern the 83 expression of these genes. 84 Melt curve analysis was used to confirm specific amplification of targets. Relative mRNA expression 135 levels were calculated using the comparative Ct method, normalised to β-actin (ACTB). 136 137
Quantitative

Chromatin immunoprecipitation 138
Briefly, 4 x 10 7 cells were fixed using 1% formaldehyde (Sigma-Aldrich) for 10 min. Cells were washed 139 in PBS and lysed using NP-40 lysis buffer. Cell nuclei were resuspended in 2 mL 0.4% SDS shearing 140 buffer for sonication with a Covaris S220X sonicator (Covaris) for 7 min. For each 141 immunoprecipitation, 25 μg chromatin was diluted with IP dilution buffer and pre-cleared with Protein 142 A agarose beads (Merck-Millipore) for 1 h at 4°C. Chromatin was incubated with 5 µL anti-CTCF 143 (Merck-Millipore), 5 µg anti-H3K27ac (abcam), or 5 µg rabbit IgG isotype control antibody (Merck-144 Millipore) for 16 h at 4°C with rotation. Immune complexes were collected by centrifugation and 145 cleared using Protein A agarose beads (Millipore) and incubated for 1.5 h at 4°C. Complexes were 146 washed and eluted in 500 μL ChIP elution buffer. Crosslinks were reversed by adding 25 μL 4M NaCl 147 and incubation for 16 h at 65°C with shaking (600 rpm). Samples were treated with RNase A and 148 Proteinase K, and DNA was purified using the QIAquick PCR Purification kit (QIAGEN) according to 149 the manufacturer's specifications using 50 μL Buffer EB. For analysis, 2 μL of purified DNA was used 150 for qPCR reactions with a Mic qPCR cycler as described above. Enrichment was determined using 151 the percent input method. 
CRISPR plasmids 168
All CRISPR plasmid constructs were modified from pSpCas9(BB)-2A-GFP (PX458), a gift from Feng 169 Zhang (48) (Addgene plasmid #48138). To generate a large genomic deletion, PX458 was modified to 170 express two guide RNAs (gRNAs) to cut the 5' and 3' ends of the target region. Guide RNAs (gRNAs) 171 were designed using CRISPRscan (49) to select highest scoring sequences with minimal off-target 172 effects (Supplementary Table 2 ). gRNAs were cloned into the BbsI restriction sites of PX458 using T4 173 DNA ligase (New England Biolabs). gRNA expression cassette inserts (U6 RNA polymerase III, gRNA 174 sequence and gRNA scaffold) were amplified using PCR with primers containing oligonucleotides with 175 Acc65I and XbaI restriction ends for sub-cloning (Supplementary Table 1 ). For the negative control 176 construct, the gRNA expression cassette of PX458 was removed using PciI/XbaI digestion and 177 purified using the QIAquick Gel Extraction kit (QIAGEN). The linearised plasmid was blunted using T4 178 DNA polymerase (New England Biolabs) and re-ligated. region between CD55 and CR2, and loci across the complement receptor genes (CR2 and CR1) 219 engaged in highly frequent interactions with loci more than 400 kb upstream near C4BPB and C4BPA 220 ( Figure 1A) . No notable interactions between these regions with downstream genes CR1L and CD46 221 were observed, indicating that chromatin interactions in this region may be directionally constrained 222 ( Figure 1A ). This pattern of interaction was consistent in 7 cell lines also examined at 10 kb resolution 223 in this Hi-C dataset, including several non-B cell types (Supplementary Figure 1A) . Interaction data 224 was unavailable in all cell lines between exon 5 -20 of CR1 ( Figure 1A , Supplementary Figure 1A ) 225 due to poor sequence mappability. Corresponding TAD co-ordinates from this dataset (30, 44) varied 226 between these cell lines, but RCA members C4BPB, C4BPA, CD55, CR2 and CR1 (exon 1 to exon 5) 227
were consistently placed within the same predicted TAD (Supplementary Figure 1B) . As TADs are 228 recognised to be constitutive between cell-types (30) , these data are consistent with the RCA gene 229 cluster being organised into more than one domain. 1B). These viewpoints included the intergenic region between CD55 and CR2 (VP1), intron 1 of CR2 237 (VP2) and intron 1 of CR1 (VP3) ( Figure 1B ). We also selected a 4C viewpoint from a CTCF binding 238 site within intron 29 of CR1 (VP4) which did not markedly engage in chromatin interactions with this 239 upstream region ( Figure 1A and Figure 1B ). We confirmed enrichment of CTCF at these VPs in the B-240 0028 cell line using ChIP-qPCR (Supplementary Figure 2) . 241 242 4C maps from VP1, VP2 and VP3 were highly similar and yielded consistent 4C signal peaks at 243 upstream CTCF sites near RCA member C4BPB and within non-RCA member YOD1 ( Figure 1B and 244 1C, asterisks), corresponding to Hi-C data ( Figure 1A ). Common interactions from these CTCF 245 viewpoints were also identified within intron 6 of CD55 ( Figure 1C , asterisks), and the intragenic 246 CTCF viewpoints in CR2 (VP2) and CR1 (VP3) interacted with the intergenic CTCF viewpoint (VP1) 247 ( Figure 1C ). Chromatin interactions from VP1 -3 did not extend to CTCF sites upstream of YOD1 or 248 downstream of CR1 exon 7 ( Figure 1C ). In contrast, VP4 produced a unique 4C map whereby 249 interactions were constrained to approximately 60 kb downstream of this viewpoint within the CR1 250 gene body and did not extend upstream ( Figure 1C ). We replicated 4C-seq from these CTCF 251 viewpoints in another B cell line (B-0056) ( Supplementary Figure 3 ), which produced a highly similar 252 interaction map whereby CTCF interactions were also organised to two discrete regions, potentially 253 representing two TADs in the RCA gene cluster. 254
255
To further delineate the TAD arrangement of the RCA gene cluster, we examined recognised 256 characteristics of TAD boundaries, including CTCF enrichment and binding site orientation, as well as 257 sequence conservation (50) . Regions flanking the RCA gene cluster (upstream of PFKFB2 and 258 downstream of CD46) and the region within CR1 between 4C viewpoints VP3 and VP4 were enriched 259 for CTCF binding ( Figure 1B not soluble protein members (C4BPB and C4BPA) (5, 11) . We confirmed this expression pattern 275 using qPCR in the B-0028 cell line ( Figure 1F ). To note, CR2 was the most highly expressed gene 276 member in this B cell model, while CR1 was the lowest ( Figure 1F ). 277
278
To identify putative enhancers in the RCA, we leveraged a novel enhancer database, GeneHancer, 279 which integrates enhancer datasets from multiple consortium-based projects and other functional 280 datasets to generate enhancer predictions and identify their potential gene-targets (51) . Confidence 281 scores for each enhancer prediction (GeneHancer score) and enhancer-gene prediction (gene-282 association score) were computationally assigned to each based on the evidence retrieved. Predicted 283 enhancers were classified as "double elite" if both their GeneHancer and gene-association scores 284 were derived from more than one source of data, representing a prediction which is more likely to be 285 functional (51) . Numerous predicted enhancers on GeneHancer were identified across TAD 1 and 286 TAD 2, but only a subset of these were classified as "double elite" (Figure 2A , 2B, Supplementary 287 Table 3 ). 288
289
Enhancers are important in cell-type specific regulation of gene expression and act by looping to their 290 target gene promoters (40) . To identify active enhancers that were most likely to be functional in B 291 cells, we examined candidate enhancer for enrichment of epigenetic marks characteristic of 292 enhancers, such as H3K27ac and DNase I hypersensitivity (DHS). We located four strong candidate 293 B cell enhancers (BENs) in TAD 1 that showed strong H3K27ac enrichment and DHS consistently in 294 both B cell lines and primary B cells were identified ( Figure 2C ). These candidate enhancers were 295 located within CD55 (BEN-1) or the intergenic region between CD55 and CR2 (BEN-2, BEN-3 and 296 BEN-4) (Table 1) . Furthermore, each candidate BEN was bound by numerous transcription factors 297 (based on ENCODE ChIP-seq data) including those important in B cell development, such as early B 298 cell factor 1 (EBF1) (52) and PAX5 (53) , and general regulatory factors (eg. EP300, CTCF and RNA 299 polymerase II) (Table 1) . To note, BEN-1 and BEN-3 were located at CTCF binding sites which were 300 involved in chromatin looping as was identified in 4C-seq maps (Figure 1 ). The four BENs identified 301 were supported by multiple lines of evidence to be active enhancer elements in B cells and were 302 prioritised for further investigation. 303 304 Predicted enhancers on GeneHancer were assigned putative gene targets using multiple methods 305 and datasets, including expression quantitative trait loci (eQTL) analysis, enhancer-promoter 306 interactions generated by capture Hi-C in the GM12878 cell line (CHi-C) and eRNA-mRNA co-307 expression from the FANTOM5 Enhancer Atlas (38, 51, 54) . Each candidate BEN was predicted to 308 regulate multiple genes, including RCA genes (C4BPA, CD55, CR2, CR1 and CD46) and non-RCA 309 genes (PIGR, FCAMR, C1orf116) ( Figure 2D , Supplementary Table 4 ). However, only interactions 310 between BEN-1 and CD55, BEN-2 and CR2, and BEN-3 and CR2, represented high-confidence 311 ("elite") associations; identified by more than one contrasting method (Figure 2E , Supplementary 312 Table 4 ). Of these, only BEN-1 was predicted to regulate a gene (CD46) located downstream of the 313 intragenic TAD boundary in CR1 ( Figure 2D ). However, this predicted interaction had the lowest score 314 among all gene-enhancer predictions for these BENs (Figure 2D , Supplementary Table 4 ). While 315 these gene-enhancer interactions were based on bioinformatic predictions, this highlighted the 316 potential for the RCA genes to be co-regulated in B cells. 317 318
Strong candidate B cell enhancers in the RCA gene cluster were functional in vitro 319
To test the functionality of each BEN, we performed luciferase reporter gene assays using a 320 constitutive minimal promoter (SV40) to drive luciferase expression. Each BEN was cloned upstream 321 of the SV40 promoter in both forward and reverse orientation and the transcriptional effects were 322 assayed in a panel of B cell lines (Reh, Raji, B-0028, SKW) and a non-B cell control (HepG2, liver 323 cell-type) (Figure 3 ). Interestingly, activity patterns of BEN-1 and BEN-3 were not consistent with that 324 of an active enhancer, such that activity was unchanged or reduced relative to the control (pGL3-P, 325 no enhancer) across the B cell lines, the latter indicative of silencer activity (Figure 3 ). BEN-4 326 displayed some enhancer activity in the B cell lines but the relative increase in transcriptional activity 327 was only significant in the SKW cell line in the reverse orientation (p = 0.0368, n = 3). (Figure 3 ). In 328 contrast, BEN-2 significantly increased luciferase activity by approximately 3-fold relative to the 329 control in SKW, in both forward (p = 0.0219, n = 3) and reverse orientation (p = 0.0436, n = 3), and by 330 1.5-fold in Raji in the forward orientation (p = 0.0003, n = 4) ( Figure 3) . Notably, transcriptional activity 331 was significantly decreased by 50% in the non-B cell line control (HepG2) in both enhancer 332 orientations (forward p = 0.0321, n = 4; reverse p = 0.0255, n = 3) ( Figure 3 ). These data, taken 333 together with bioinformatics, indicated that BEN-2 was the most likely candidate BEN to be active in 334 As reporter gene assays remove regulatory elements from their genomic context, which is an 348 important aspect of enhancer function, we sought to assess the functional activity of BEN-2 in vivo. 349
We also wished to confirm the predicted gene targets of BEN-2 identified on GeneHancer, including 350 CD55 and CR2 which directly flank the enhancer (Figure 2 ). CRISPR deletion machinery was 351 delivered using a plasmid-based method into the Raji mature B cell line, which expresses CD55, CR2 352 and CD46, but CR1 is not expressed at levels detectable by qPCR ( Figure 5A ). This pattern of gene 353 expression is in accordance with other B cell lines, such as B-0028 ( Figure 1F ). We modified the 354 PX458 CRISPR plasmid to express two guide RNA sequences (gRNA) that cut either side of BEN-2 355 (g1g2 or g3g4) to delete a 4 kb region encompassing the enhancer ( Figure 5B ). The CRISPR 356 plasmids, containing a GFP marker, was delivered into Raji cells and successfully transfected GFP-357 positive cells were enriched by fluorescence activated cell sorting (FACS). Successful enhancer 358 deletion within the enriched cell populations was confirmed by PCR ( Figure 5B and Figure 5C ). 359 360 CRISPR deletion of BEN-2 with g1g2 significantly decreased CR2 transcript abundance to 361 approximately 30% of WT levels (p = 0.0184, n = 3) and CD55 to approximately 50% of WT levels (p 362 = 0.0167, n = 3) ( Figure 5C ). A no-guide construct expressing only Cas9 and GFP did not result in 363 enhancer deletion ( Figure 5B ) or significantly alter mRNA expression of these genes in wild-type Raji 364 cells (WT) ( Figure 5C ). To account for potential off-target effects with g1g2, we repeated the deletion 365 using an additional pair of guide sequences (g3g4). In agreement with altered transcript abundance 366 from deletion of BEN-2 with g1g2, expression of CR2 and CD55 were both decreased in the enriched 367 g3g4 population in comparison to WT. The decrease in CR2 expression was less extensive with g3g4 368 (approximately 60% of WT levels), but this was still significant compared to the NG control (p = 369 0.0213, n = 3). Expression of CD55 was significantly reduced to similar levels in both g1g2 and g3g4 370 enriched population (g3g4 p = 0.0281, n = 3). We also measured transcript abundance of CD46, 371 which was not predicted to be targeted by BEN-2 on GeneHancer and located to the neighbouring 372 TAD (Figure 1 ). Enhancer deletion with either guide combination did not alter CD46 transcript 373 abundance ( Figure 5C ). These data confirmed that BEN-2 is a functional enhancer in B cells and 374 functionally demonstrate that it regulates CD55 and CR2 within this cellular context. 375 376 CR2 (CD21) is a well-established marker for B cell maturity (55) and surface expression of CR2 is 377 highly robust in the Raji B cell line (56) ; representative of a mature B cell (57) . As CR2 transcript 378 levels were significantly decreased with BEN-2 CRISPR deletion in the Raji cell line, we next 379 determined if CR2 surface protein expression were concomitantly affected. We used flow cytometry to 380 assess CR2 surface expression in the polyclonal FACS-enriched populations used and observed 381 decreases that correlated well with corresponding transcript decreases ( Figure 6 ). A decrease in CR2 382 expression was observed in g1g2 populations relative to WT across three biological replicates (Figure  383 6A). To quantify the decrease in CR2 surface expression more definitively, we gated the WT 384 population based on side scatter (SSC-A) versus CR2-PE into four quadrants such that the CR2-385 positive cells were equally divided into Q3 and Q4, and then applied this gate to the CRISPR FACS-386 enriched populations. We observed a reduction in CR2-positive cells in Q3 from 53% to 39.7%, with a 387 concomitant increase in cells in Q4 (WT Q4 = 47.0%, g1g2 Q4 = 60.3%) ( Figure 6B ). In line with CR2 388 transcript abundance data ( Figure 5C ), CR2 surface expression was unchanged in the NG 389 populations and decreased in the g3g4 population relative to WT (Supplementary Figure 5 ). This 390 confirmed that the reduction in CR2 transcript expression with CRISPR deletion of BEN-2 also 391 reduced surface protein levels, and thus further validates that BEN-2 regulates CR2 both at the level 392 of mRNA and subsequent protein receptor expression in a B cell context. 393 DISCUSSION 395 396 Here, we have explored for the first time how chromatin architecture governs the RCA gene cluster 397 and demonstrated that its members are transcriptionally co-regulated by common long-range 398 mechanisms. Using high-resolution 4C-seq maps in B cell models, we showed that several distal 399 CTCF sites in the RCA gene cluster interact with one another, representing physical chromatin 400 looping and defining a functional role for these CTCF sites in this cell type. This includes the CTCF 401 site modulated by SLE-associated SNP (rs1876453) (27) , revealing an extensive and complex 402 mechanism by which this genetic variant may influence gene expression and autoimmunity. CTCF-403 mediated chromatin looping was constrained to one of two distinct regions despite the broad 404 distribution of CTCF sites across the entire gene cluster, illustrating that the RCA spans two adjacent 405 TADs in B cells and separating the members of the human RCA gene cluster into TAD 1 (C4BPB, 406 C4BPA, CD55, CR2 and CR1) or TAD 2 (CR1L and CD46). 407 408 Unexpectedly, the interactions of the two CTCF sites within CR1 diverged to in TAD 1 or TAD 2, 409 partitioning the CR1 promoter to TAD 1 and indicating that the boundary between the two TADs in the 410 RCA gene cluster is positioned within the body of the CR1 gene. We also identified convergent CTCF 411 sites flanking each domain, supporting the positioning of this TAD boundary in line with loop extrusion 412 model of TAD formation (31) . To our knowledge, a TAD boundary distinctly located within the body of 413 an expressed protein-coding gene has not been characterised before and the question remains as to 414 if this novel TAD boundary directly influences CR1 expression itself. 415 416 This boundary element was not investigated further in this study as Hi-C and 4C interaction data were 417 missing within CR1 in the vicinity of this boundary. This is due to a well-characterised tandem 418 segmental duplication within CR1 known as 'low copy repeat 1' (LCR1) which results in different 419 structural alleles of CR1 (58, 59) ; CR1-A (two copies of LCR1) and CR1-B (one copy of LCR1) alleles 420 are most common (60) . As LCR1 is 18 kb in size and possesses more than 99% sequence identity, it 421 is not amenable to sequencing-based technologies, including 4C and Hi-C. Missing Hi-C interaction 422 data has been shown to influence computational TAD calls (61) . Thus the missing data at LCR1 likely 423 explains why the predicted TADs from Dixon et al. (30) , differed to the TAD organisation we 424 uncovered. Nonetheless, both these data are complimentary. Interestingly, LCR1 has had a long-425 standing genetic association with SLE (62), but the impact of this repeat on the biological function of 426 CR1 and how it contributes to disease susceptibility has remained unknown. Our findings highlight the 427 importance of validating TAD predictions from Hi-C using complimentary methods (39) , and propose 428 that the effect of different copy numbers of LCR1 may influence the topological architecture of RCA 429 gene cluster in the B cell lineage. 430
431
The CR1 boundary element and TAD organisation of the may be pertinent from an evolutionary 432 perspective. In mice, the RCA gene cluster is conserved but separated to two chromosomal positions 433 located more than 6 Mb apart (63) , matching closely to the TAD organisation of the gene cluster we 434 identified. Notably, there are some key differences between RCA members in humans and mice. In 435 humans, CR2 and CR1 are encoded by separate genes, while mouse CR2 and CR1 are expressed 436 from a single gene, Cr2, through alternative splicing (64) . It has been observed that breaks in synteny 437 between species commonly occur at TAD boundaries (65) , thus the TAD boundary we identified in 438 CR1 may represent the breakpoint region for the genomic rearrangement of the RCA or complement 439 receptor genes in humans and mice. 440 441 Importantly, the chromatin organisation of the RCA gene cluster we uncovered indicated that there 442 are two distinct regulatory landscapes which control its members in B cells. We observed direct 443 physical interactions between several expressed gene members in TAD 1, including CD55 and CR2, 444 forming a strong basis for these genes to be regulated by enhancers and transcriptionally co-445 regulated in this cell type. Indeed, we able to establish this through the identification of a functional 446 intergenic enhancer, BEN-2, in TAD 1. We showed that BEN-2 is an active enhancer in B cells by 447 characterising its transcriptional activity and chromatin marks in several B cell models. Genomic 448 deletion of BEN-2 in the Raji B cell line resulted in significant decreases in CR2 and CD55 mRNA 449 expression, which confirmed that BEN-2 is functional enhancer in B cells and that it regulates the 450 expression of both these genes. Additionally, deletion of this enhancer did not influence the RCA 451 gene in TAD 2 (CD46), indicating that the TADs in the RCA cluster function to restrict enhancers to 452 target genes within the same TAD. It is possible that BEN-2 also regulates CR1 in TAD 1, as 453 predicted by CHi-C in the GM12878 B cell line (54) . Altogether, we showed that chromatin looping 454 and TADs in the RCA gene cluster functions, in part, to bring long-range elements to gene promoters 455 and established for the first time that the RCA cluster is transcriptionally co-regulated. 456
457
This finding has a number of potential implications in B cell biology and autoimmunity. In addition to 458 improving our understanding of CR2 and CD55 transcriptional regulation, we showed that deletion of 459 BEN-2 reduced and sustained CR2 mRNA expression to levels which also diminished CR2 protein 460 levels at the cell surface. As receptor expression of CR2 on B cells is directly involved in modulating 461 antibody production (15) , this finding highlights an important role for BEN-2 in the control of CR2 462 expression and the potential for altered BEN-2 enhancer activity to influence B cells at the functional 463 level. By revealing that BEN-2 regulates the transcription of these genes in B cells simultaneously, we 464 have established a clear gene-gene interaction between CR2 and CD55. The expression of CD55 on 465 B cells has been also shown to be altered in SLE patients (66, 67) , as has been similarly 466 demonstrated for CR2 (18, 19) . As these regulators share key functions in complement and both have 467 known roles in SLE, alterations to the expression of both genes through BEN-2 or chromatin looping 468 could considerably impair immune response and B cell autoimmunity. 469 470 Our findings also define an important non-coding region in the RCA gene cluster situated in TAD 1 471 between CD55 and CR2. This region encompasses BEN-2, as well as also several strong candidate 472 regulatory elements. The transcriptional activity of all candidate enhancers we assessed in this study 473 deviated from the control in at least one B cell line in luciferase assays, indicative of regulatory 474 potential in this cell type. Intriguingly, two of the candidate enhancers (BEN-1 and BEN-3 ) 475 demonstrated a pattern of regulatory activity in B cells consistent with that of a silencer. To note, 476 these candidates were the only two indicated to bind CTCF; a known insulator of gene expression 477 (29) . Given that the majority of disease-associated variants map to non-coding regulatory regions 478 (36) , it will be of interest to investigate genetic variants within this region to identify potential 479 associations with SLE susceptibility. 480 481 Among BEN-2 and the candidate enhancers in TAD 1, only one predicted enhancer-gene interaction 482 out of 16 crossed into TAD 2 (BEN-1 and CD46) , emphasising the partition between the two domains 483 of the RCA gene cluster. While these results are only based on bioinformatic data, this reveals the 484 potential extent to which transcriptional co-regulation may occurs in the RCA. This is of particular 485 interest as the RCA members are expressed on cell types other than B cells, and have unique 486 expression patterns individually. For example, CD55 and CD46 are expressed across many cell types 487 (5, 11) , whereas CR2 and CR1 are predominantly expressed on B cells (68) and erythrocytes (69) , 488 respectively. Investigation of the chromatin architecture and long-range regulation of the RCA gene 489 cluster in other immune cell types will uncover the extent to which these genes are transcriptional co-490 regulated, the long-range mechanisms which control RCA genes and how this is dysregulated in the 491 context of autoimmunity. 492
493
In conclusion, we have shown that the RCA gene cluster comprises of a complex network of 494 enhancer-gene and gene-gene interactions (epistasis) with a distinct three-dimensional genome 495 structure in the B cell lineage. Indeed, epistasis has been a long-recognised contributor to complex 496 disease susceptibility but is often unaddressed, particularly due to the difficulty in identifying such 497 interactions (70) . We used chromatin maps and functional analyses to define such interactions at the 498 molecular level in the RCA gene cluster and identify novel co-regulatory mechanisms which 499 collectively govern these key immunomodulatory genes. In sum, we have revealed novel mechanisms 500 by which the RCA gene cluster is controlled, expanding the scope for future investigations in the 501 context of evolution, immunity and complex genetic disease. 502 A. The structural organisation of the RCA genes (dark blue) and upstream genes (grey) PIGR, FCAMR, C1orf116 and YOD1 on hg19 (chr1:207,104,491-207,978,031). B. Putative enhancers were identified by GeneHancer from multiple datasets from different consortia, such as ENCODE, Ensembl and FANTOM5 (GeneHancer). Each putative enhancer was also assigned predicted gene targets based on one or more methods. However, only a subset of putative enhancers were classified as 'double elite' on GeneHancer (Double elite). C. Four candidate B cell enhancers (yellow) were identified using ENCODE data for H3K27ac enrichment and DNase I hypersensitivity in different B cell samples (GM12878 B cell line and primary B cells from peripheral blood). CTCF ChIP-seq signal for the GM12878 B cell line from ENCODE is also shown. D. Candidate B cell enhancers were predicted to regulate multiple genes. Target gene predictions that were identified by more than one method in GeneHancer are represented by a solid line. Predictions that were identified by just one method are represented by a dotted line. The opacity of each line represents the relative score/confidence for each geneenhancer prediction as determined by GeneHancer whereby higher confidence predictions are darker. E. Region across CD55, CR2 and CR1 (exon 1 -6) on hg19 (chr1:207,484,047-207,700,935).
ACCESSION NUMBERS
Candidate B cell enhancers (BEN) were named based in order of chromosomal position (BEN-1, BEN-2, BEN-3 and BEN-4) . Evidence for BENs to regulate CD55, CR2 and CR1 was strongest among all gene-enhancer predictions. (EBF1, IRF4 , PAX5, RELA, SPI1) and gene regulation or chromatin organisation (CTCF, POL2RA and EP300) assayed using ChIP-seq in ENCODE are listed. * These predicted enhancers and gene-enhancer interactions were identified using more than one method by GeneHancer.
Figure 3: Candidate B cell enhancers demonstrated regulatory potential in luciferase assays, and BEN-2 increased relative transcriptional activity across a panel of B cell lines.
Enhancer constructs for strong candidate B cell enhancers were cloned into the pGL3-P (Promega) luciferase plasmid, upstream of an SV40 minimal promoter in forward (blue) and reverse (orange) orientation. Bars represent mean relative luciferase activity ± SEM after normalisation to an empty pGL3-P (no enhancer) control plasmid (n = 3 to 8). Asterisks represent statistically significant differences between normalised values and the pGL3-P control (p < 0.05). Dotted line at y = 1 represents normalised pGL3-P control value. A. Cell surface protein expression of CR2 protein was determined using flow cytometry. Cells were labelled with PE-conjugated CR2 antibody or PE-conjugated IgG (isotype control) to confirm CR2-positive expression. Samples were also run alongside unstained and singlecolour compensation controls (not shown). For each sample, 50,000 events were collected. Results were consistent across three biological replicates. B. WT Raji cells were labelled with CR2-PE were gated based on side-scatter versus CR2-PE into four quadrants such that the proportion of cells in Q3 and Q4 were approximately equal. This gate applied to the CR2-PE stained CRISPR enhancer deleted g1g2 population to quantitatively assess shift in CR2-positive cells.
Supplementary Figure 1: Hi-C and TAD predictions across several cell-types corresponded to 4C-seq maps and indicated that the RCA gene cluster is divided into two TADs.
A. Raw Hi-C data at 10 kb resolution from Rao et al. for the 1 Mb region across the RCA genes (dark blue) on hg19 (chr1:207,120,000-208,130,000), as shown in Figure 1 . Highly frequent chromatin interactions between C4BPB, C4BPA, CD55, CR2 and CR1 in GM12878 were observed in all cell lines assessed in this dataset (arrows). B. Predicted TAD co-ordinates from Dixon et al. varied between different cell lines, but RCA genes C4BPB, C4BPA, CD55, CR2 and the CR1 promoter were consistently situated in the same TAD (dotted lines). A boundary at exon 5 of CR1 (hg19 chr1:207,700,000) was identified in NHEK, IMR90, KBM7 and HUVEC cell lines.
A B
500 kb Supplementary Table 4 : Strong candidate B cell enhancers (BENs) were predicted to regulate genes on GeneHnacer using eQLT analyses, promoter interactions from capture Hi-C (CHi-C) and/or enhancer RNA and mRNA co-expression (eRNA).
BEN-1 BEN-2 BEN-3 BEN-4
Non-RCA
PIGR
Method
CHi-C Score 9.7
FCAMR
Method
C1orf116
Method CHi-C * These predicted gene-enhancer interactions were identified using more than one method on GeneHancer.
